Maravai LifeSciences completed the acquisition of MyChem for $240m.

Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, completed the acquisition of MyChem, a privately held provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets, for $240m. "MyChem’s chemically synthesized nucleotides are a natural fit and complementary product line for our Nucleic Acid Production business. We have worked with MyChem since 2018 and have the highest regard for the founders and the team they have built and believe there is a close alignment of company cultures. Similar to our past acquisitions, MyChem is founder-led with exceptional science in place where we can help scale the organization and accelerate growth," Carl Hull, Maravai CEO.